A novel diagnostic four-gene signature for hepatocellular carcinoma based on artificial neural network: Development, validation, and drug screening
Source check: Source checked. Not independent scientific confirmation.
Finding: A four-gene artificial-neural-network signature (MT1M, SPINK1, AKR1B10 and SLCO1B3) distinguished hepatocellular carcinoma in training and testing datasets, with ROC AUCs of 0.910 and 0.953. qRT-PCR and cell-viability assays provided additional checks; the diagnostic result remains based on retrospective datasets. The result remains bounded to the reported datasets and assays.
Technology: Artificial neural network
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- An artificial neural network classified hepatocellular carcinoma from a four-gene signature selected from expression datasets.
- Test and result
- A four-gene artificial-neural-network signature (MT1M, SPINK1, AKR1B10 and SLCO1B3) distinguished hepatocellular carcinoma in training and testing datasets, with ROC AUCs of 0.910 and 0.953. qRT-PCR and cell-viability assays provided additional checks; the diagnostic result remains based on retrospective datasets.
- Limitation / still unknown
- The source-checked evidence does not establish broader external validity or prospective benefit. Affiliation was not available in the retrieved trusted primary metadata.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://www.frontiersin.org/journals/fgene/articles/10.3389/fgene.2022.942166/full
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.